


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.42%
+15.38%
-17.88%
INKT
MiNK Therapeutics
$13.51
INKT Price Performance
$11.04 (+22.37%)
$12.55 (+7.65%)
$14.78 (-8.59%)
$8.57 (+57.64%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Analysts perspectives on the stock desirability, trend direction and growth potential
INKT has Low risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
What is INKT current stock price?
What are INKT stock strengths?
What is INKT Risk Level?
What is INKT market cap and volume?
What is INKT current Stock IQ?
Should I buy INKT stock right now?
Is INKT a Strong Buy right now?
What does a 'Strong Buy' rating mean for INKT?
What does a 'Strong Sell' rating mean for INKT?
What factors influence INKT's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
INKT
MiNK Therapeutics
Current Price
$13.51

INKT Price Performance
$11.04 (+22.37%)
$12.55 (+7.65%)
$14.78 (-8.59%)
$8.57 (+57.64%)
INKT Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Analysts perspectives on the stock desirability, trend direction and growth potential
INKT has Low risk level
Risk Indicators
INKT Stock IQ
Stock Insights
Not Enough Information
INKT Latest Analysis
MiNK Announces Collaboration To Advance PRAME-Targeted INKT Cell Therapy For Pediatric Cancers . (RTTNews) - Shares of MiNK Therapeutics Inc. (INKT) are up by 73% in the pre-market following the announcement of a strategic collaboration with C-Further an international pediatric oncology consortium to advance a PRAME-targeted iNKT cell therapy for children with cancer.
Tue Mar 10, 2026
MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers.
Tue Mar 10, 2026
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers. NEW YORK March 10 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases today announced a strategic collaboration with C-Further an international pediatric oncology therapeutics consortium enabled by Cancer Research Horizons LifeA
Tue Mar 10, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INKT Stock trends
INKT Stock performance
INKT Stock analysis
INKT investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.